Remove Access Remove Banking Remove Clinical Trials Remove Events
article thumbnail

Press Release: Maya and National Psychedelics Association Announce Partnership to Support Psilocybin-Assisted Services in Oregon

Cannabis Law Report

As Oregon prepares to roll out the nation’s first legal psilocybin-assisted services program, there is a recognized need for the community to track adverse events and measure efficacy. NPA’s mission is to ensure all Americans get the support they need to safely access psychedelic-assisted care. ABOUT MAYA.

article thumbnail

Chemistree Investee ImmunoFlex™ Completes Clinical Study and Submits US and International Patent Applications

Cannabis Law Report

ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. Forward-looking statements are statements that relate to future, not past, events. For more information, visit www.Chemistree.ca. SOURCE Chemistree Technology Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Cannabis Law Report

“I am so very proud of all Anebulo has achieved over the past 18 months, including building out a highly effective team, securing new intellectual property protection, preparing and starting a proof-of-concept clinical trial, advancing regulatory discussions with the U.S. and Australia. About Anebulo Pharmaceuticals, Inc.

article thumbnail

MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), tumor necrosis factor receptor I (TNFRI) and IL-6. MyMD Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

article thumbnail

MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia

Cannabis Law Report

3 MyMD believes that there are no FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be at least $600 billion by 2025 according to a major investment bank. In the United States, the estimated cost of hospitalizations in individuals with sarcopenia is estimated at $40.4 4 [link].

article thumbnail

First ethics at MAPS in question and now Australia’s Mind Medicine look to have some serious integrity issues too

Cannabis Law Report

Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. The charity was eventually instructed to pull an advertisement for the study by the ethics committee that conditionally approved the trial.

article thumbnail

Virpax to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com on October 7, 2021

Cannabis Law Report

The presentation can be accessed by registering (at no cost) for the Investor Forum at www.channelchek.com ; the investor portal created by Noble. Noble Capital Markets (“Noble”) is a research driven boutique investment bank that has supported small & microcap companies since 1984. Eastern time. www.youtube.com/channelchek.